Genitourinary Cancer
Conference Coverage
Nephrectomy may benefit select renal cancer patients based on risk factors
CHICAGO – CARMENA update confirms cytoreductive nephrectomy should not be standard of care for most cases of metastatic renal cell carcinoma.
Conference Coverage
Novel enfortumab vedotin induces responses in advanced urothelial cancers
CHICAGO – The investigational drug showed encouraging responses in patients with heavily pretreated locally advanced...
Conference Coverage
ENZAMET trial: Early enzalutamide delays progression, improves survival in mHSPC
CHICAGO –Enzalutamide with standard first-line testosterone suppression delays progression and improves survival in...
Conference Coverage
TITAN trial yields big survival benefits in mCSPC
CHICAGO – Adding apalutamide to androgen deprivation therapy significantly improved overall survival of castration-...
Conference Coverage
Short-term ADT improves radiation salvage after prostatectomy
CHICAGO – 10-year metastasis-free survival was superior for patients who received goserelin plus radiation for...
Conference Coverage
Trial matches pediatric cancer patients to targeted therapies
Nearly a quarter of the patients screened as part of the National Cancer Institute–Children’s Oncology Group Pediatric MATCH trial have been...
From the Journals
Equal access to care for black men lowers risk of prostate cancer-specific mortality
After adjustment for race-based imbalances such as access to care and standardized treatment, there was no significant difference in prostate...
How I will treat my next patient
Enzalutamide in castration-sensitive prostate cancer and ctDNA to monitor early colorectal cancer
Dr. Lyss breaks down the results of the ARCHES trial and new data on ctDNA monitoring in early colorectal cancer.
From the Journals
ARCHES: Enzalutamide improves mHSPC survival regardless of baseline PSA
For men with metastatic hormone-sensitive prostate cancer, enzalutamide with ADT offers longer radiographic progression-free survival compared...